The first of two developmental switches in human hemoglobin expression involves the down-regulation or silencing of the embryonic epsilon-globin gene. We have previously reported a silencer element (epsilon GS) in the 5' flanking region located at -270 bp 5' to the cap site of the epsilon-globin gene that provides negative regulation for this autonomously regulated gene. We now have extended this analysis 5' as far as to the globin locus control region (LCR) and have identified several functionally important cis-elements that markedly affect the epsilon-globin promoter. We use reporter gene constructs with deletion mutations in the 5' epsilon-globin DNA and transient transfection and DNA-protein binding assays. A series of negative and positive elements are present along the 6 kb of 5' epsilon-promoter, including two strong negative control elements located at -3 kb and -1.7 kb, designated as epsilon-NRA and epsilon-NRB, respectively. In addition, we have identified several positive elements in this sequence. These data suggest the complexity of globin switching, in this case the down regulation of epsilon-globin gene. Several DNA motifs for the erythroid specific transcription factor GATA-1 within the negative control element epsilon-NRA have been identified and characterized. The study suggests that besides epsilon-GS, the epsilon-globin gene switch-off requires the combined actions of these multiple negative elements. Identifying the cis-acting regulating elements in the 5' region of the epsilon-globin gene and elucidating the mechanism of epsilon-globin gene silencing may provide an understanding about the coordinated regulation of the entire beta-globin cluster. This project has been combined with

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK025016-24
Application #
6105128
Study Section
Special Emphasis Panel (LCB)
Project Start
Project End
Budget Start
Budget End
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
?oki?, Vladan P; Mojsilovi?, Slavko; Jaukovi?, Aleksandra et al. (2015) Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia. Blood Cells Mol Dis 55:373-81
Schechter, Alan N; Perlman, Robert L (2009) Evidence-based medicine again. Perspect Biol Med 52:161-3
Cokic, Vladan P; Beleslin-Cokic, Bojana B; Noguchi, Constance T et al. (2007) Hydroxyurea increases eNOS protein levels through inhibition of proteasome activity. Nitric Oxide 16:371-8
Oneal, Patricia A; Gantt, Nicole M; Schwartz, Joseph D et al. (2006) Fetal hemoglobin silencing in humans. Blood 108:2081-6
Cokic, Vladan P; Beleslin-Cokic, Bojana B; Tomic, Melanija et al. (2006) Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 108:184-91
Taniuchi, Hiroshi; Schechter, Alan N; Shiloach, Joseph (2004) Linderstrom-Lang-Schellman's model for protein stabilization revisited. Curr Protein Pept Sci 5:275-86
Beleslin-Cokic, Bojana B; Cokic, Vladan P; Yu, Xiaobing et al. (2004) Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104:2073-80
Byrne, Karen M; Leitman, Susan F; Schechter, Alan N et al. (2003) Increasing oxygen tension improves filtration of sickle trait donor blood. Br J Haematol 122:678-81
Cokic, Vladan P; Smith, Reginald D; Beleslin-Cokic, Bojana B et al. (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 111:231-9
Smith, Reginald D; Brown, Benjamin; Ikonomi, Pranvera et al. (2003) Exogenous reference RNA for normalization of real-time quantitative PCR. Biotechniques 34:88-91

Showing the most recent 10 out of 14 publications